President Trump’s in a single day resolution to impose a 100% tariff on imported prescription drugs beginning October 1 is already whacking the inventory costs of overseas drug firms as analysts wrestle to digest how damaging the hit to the drug enterprise shall be.
“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” the president mentioned on social media. “‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”
This morning, Asian drug firms noticed their market caps trimmed as merchants bailed out of overseas drug shares.
“Investors got a fresh reminder about the trade war, and the impact has already been evident in Asian markets. For instance, pharmaceutical companies have been among the worst performers this morning in Japan’s Nikkei (-0.46%), with losses for Chugai Pharmaceutical (-5.12%) and Sumitomo Pharma (-5.21%),” Jim Reid and the group at Deutsche Financial institution advised purchasers immediately.
In Europe, Denmark’s Novo Nordisk fell 0.43%. Switzerland’s Roche was marginally down. France’s Sanofi, counterintuitively, was up 0.33% premarket (however that’s in all probability a useless cat bounce as a result of it misplaced practically 3% the day earlier than).
Within the U.S., against this, Pfizer rose 0.64% premarket. Eli Lilly was up 1.13%. Bristol-Myers Squibb grew 0.65%.
On its face, 100% tariffs look harsh. “Asia supplies just over 20% of US pharmaceutical imports by value, a meaningful commercial hit for U.S. consumers at face value,” Oxford’s Lavatory wrote. However that means the White Home shall be pressured to calm down some requirements, she mentioned. “We therefore expect the US to follow up with announcements detailing protections for some categories of products, blunting the effective tariff burden.”
The loopholes that can blunt the influence of the brand new tariffs are:
- Generic medicine should not included.
- Corporations that may present an in-progrerss building website could be excluded.
- Corporations in Japan and Korea “are effectively shielded by trade-deal safeguards,” Lavatory added.
UBS’s Paul Donovan mentioned the identical: “The 100% pharmaceutical tariff applies only to branded drugs, and constructing a factory may lead to an exemption. Many pharmaceutical companies have facilities in the U.S., so it may be relatively easy to superficially expand those facilities to avoid tariffs being applied.”
Actually, many U.S. firms may be shielded. A dozen or extra drug firms have promised to spend $350 billion this 12 months in manufacturing and R&D within the U.S., based on the Wall Road Journal.
Nonetheless, Huge Pharma is formally sad. “[Drug] companies continue to announce hundreds of billions in new U.S. investments,” a spokesperson for the Pharmaceutical Analysis and Producers of America advised the WSJ. “Tariffs risk those plans because every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures.”
Fortune International Discussion board returns Oct. 26–27, 2025 in Riyadh. CEOs and world leaders will collect for a dynamic, invitation-only occasion shaping the way forward for enterprise. Apply for an invite.
